// App-Quantinova.ai

TCT-456 : Direct Implantation of Rapamycin-Eluting Stents with Bioresorbable Drug Carrier Technology Utilizing the Svelte Coronary Stent-on-a-Wire: 2-Year Follow-Up of the Randomized, Controlled DIRECT II Study

Researchers

Presenter

  • Stefan Verheye

Principal Investigators

  • Pieter Stella

  • Didier Carrie

  • Ahmed Khattab

  • Ton Slagboom

  • Jozef Bartunek

Medical Centers

  • Hopital Rangueil, Toulouse, France

  • Cardiovascular Institute Middelheim, Antwerp, Belgium

  • University Medical Center Utrecht, Utrecht, Netherlands

  • University Hospital Basel, Basel, Switzerland

  • Cardiovascular Center, OLV Hospital, Aalst, Belgium

  • VUmc, Amsterdam, Netherlands

Locations

  • France

  • Switzerland

  • Belgium

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Coronary Artery Disease

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Rapacan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved